Athersys, Inc. Unveils Exciting $3.5 Million Public Offering: Embarking on a New Financial Frontier

Thrilling Financial Venture Unfolds in Cleveland!

In an electrifying move, Athersys, Inc. (Nasdaq: ATHX) has just unveiled its captivating “reasonable best efforts” public offering. Brace yourselves for a remarkable opportunity as the company presents 10,937,500 shares of common stock (or their equivalents) at an irresistible price of $0.32 per share.

But that’s not all – the excitement doesn’t stop there! Athersys is taking it up a notch by offering Series A Warrants and Series B Warrants to investors. These golden tickets grant access to an astonishing aggregate of 10,937,500 shares of common stock each. Imagine the possibilities as these warrants come with an exercise price of $0.32 per share and can be exercised right after issuance, with expiration dates set at five years and one and a half years, respectively.

Mark your calendars for August 21, 2023 – that’s when the curtains close on this heart-pounding offering, subject to customary closing conditions, of course. With a whopping expected gross proceeds of approximately $3.5 million, the financial landscape is about to change. Hold onto your hats as Athersys plans to harness these funds for their thrilling journey of general corporate purposes.

And who’s leading the way in this adrenaline-packed endeavor? None other than A.G.P./Alliance Global Partners, the sole placement agent for this extraordinary offering. Get ready to be part of a financial tale like no other!

The thrilling opportunity lies within the securities outlined above, ready to set the financial world abuzz. Envision a canvas painted with potential, as we present these securities under the spotlight of Form S-1 (File No. 333-273256), a masterpiece registered with the vigilant eye of the Securities and Exchange Commission (SEC), springing to life on that momentous day of August 11, 2023. This isn’t just an offering; it’s a symphony of possibilities orchestrated by a prospectus that’s not just paperwork, but a key to your financial dreams.

Don’t miss the chance to be part of this narrative – a narrative you can join by delving into the preliminary prospectus, and soon, the final masterpiece, both of which await you in the digital galleries of the SEC’s website. Your digital journey doesn’t stop there; A.G.P./Alliance Global Partners awaits to guide you further into this saga of potential, perched at their strategic outpost at 590 Madison Avenue, 28th Floor, New York, NY 10022. The spotlight’s on you, seize the chance!

In a move that’s as bold as it is strategic, Athersys has stepped onto the stage of innovation once again. Picture this: existing warrants, like hidden treasures, are being polished and reimagined. Imagine holding the key to unlock a realm of potential, with these warrants initially set to snag 9,109,090 shares of common stock, each at a price of $1.10 per share, and an expiration date of November 10, 2027.

But hold onto your seats, for the tale takes an intriguing twist! As part of a grand transformation that unfolds with the closing of this offering, these warrants are shedding their old skins. The metamorphosis includes a striking reduction in exercise price, now a mere $0.32 per share, beckoning you to seize the opportunity like never before.

And the clock’s tick? It extends to August 21, 2028, adding a suspenseful urgency to the mix. Imagine holding in your hands not just warrants, but a ticket to an augmented future. Amidst all this change, some things stand steady: the unaltered terms of these warrants that continue to echo promises of potential. Athersys is setting the stage, will you claim your part in this narrative?

Step into a world where the dance of opportunity is set in motion, but beware: this press release is not the opening note of a sale symphony, nor is it the captivating call to acquire these securities. We’re charting a course through the legal tapestry, ensuring that no sale of these coveted securities occurs in any state or realm where the laws haven’t yet granted them permission to shine.

This isn’t a mere formality; it’s a dance of legality, a choreography that ensures every move is harmonious with the regulations of the land. So, before the curtains of acquisition rise, before the spotlight of sale illuminates, the script must adhere to the laws that govern each state and domain. Picture it: the careful steps to registration, the intricate moves to qualification. It’s a tale where legality and opportunity waltz hand in hand, crafting a narrative that’s as mesmerizing as it is responsible.

About Athersys

Athersys stands at the forefront of biotechnology, driven by a passionate commitment to revolutionizing human well-being. Our journey is marked by the relentless pursuit of therapeutic breakthroughs that amplify the tapestry of life itself.

Anchored in innovation, we’re unveiling MultiStem® – a pioneering stem cell therapy, meticulously crafted from adult sources. It’s a beacon of hope for neurological, inflammatory, immune, and critical care realms, with ongoing trials illuminating its immense potential. Brace yourself, as we’re not confined to traditional avenues; our vibrant updates might dazzle your social feeds.

Surf through our digital realm and join the exhilarating saga on Twitter. While the future beckons with possibilities, remember that our posts, sparkling with information, might carry a touch of the extraordinary. Embrace the excitement, but tread thoughtfully, for our words may hold the power of foresight. As the stars of progress realign, we invite you to dance with us through the cosmos of potential.

Leave a Comment